dyslipidemias การใช้

• Should not be used in patients with the following : type 1 diabetes, diabetic ketoacidosis, pancreatitis, Fredrickson types I and V dyslipidemias, and severe renal impairment.
• "' Catabasis Pharmaceuticals "', founded in 2008 and based in Cambridge, Mass ., is a clinical-stage biopharmaceutical company developing bi-functional small molecules for treatment of dyslipidemias and inflammatory diseases.